FEops’ simulation technology uses advanced computational modeling and simulation, initiating from HyCT’s IBITECH lab, to provide manufacturers and physicians with pre-operative insights into the interaction between patient anatomy and heart implants. One example is FEops HEARTguide™. It is available on the European and Canadian market with indication for use in TAVI and LAAo. Outside Europe and Canada, FEops HEARTguide™ is only available for non-clinical use.
By combining routine preoperative CT images with patient-specific CM&S, FEops HEARTguide™ predicts the interaction between the TAVI device and the patient’s unique anatomy, including post-implantation deformation, allowing physicians to assess the risk for aortic regurgitation and conduction abnormalities. Considering the extension of TAVI indications to younger, lower-risk patients (of which many have bicuspid aortic valves), these insights are key. Among these patients, the chance of complications such as paravalvular regurgitation and new permanent pacemaker remains high. This illustrates the need to more effectively risk-stratify bicuspid and lower risk aortic valve patients.
Using FEops HEARTguide™ in bicuspid aortic valve cases gives physicians detailed preoperative information about the interaction between the replacement valve and the patient’s anatomy – helping them improve outcomes and minimize risk.